Literature DB >> 6590568

Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine.

C Luisi-DeLuca, T Mitchell, D Spriggs, D W Kufe.   

Abstract

We have previously demonstrated that continuous exposure of human HL-60 human promyelocytes to 1-beta-D-arabinofuranosylcytosine (ara-C) results in the induction of terminal differentiation to monocyte-like cells. The present study extends these findings by demonstrating that ara-C induces hemoglobin synthesis in human K562 erythroleukemia cells. This effect occurs maximally at an ara-C concentration (5 X 10(-7) M) that results in K562 cytostasis. In contrast to the reversible effects of hemin and hydroxyurea on globin synthesis in this cell line, we have found that the induction of K562 hemoglobin synthesis by ara-C is irreversible. An induction of K562 hemoglobin synthesis also occurs with aphidicolin, another inhibitor of S-phase DNA synthesis, but not with vinblastine, an inhibitor of mitosis. Finally, ara-C induction of a differentiated K562 phenotype is accompanied by the loss of self-renewal capacity, a finding consistent with terminal differentiation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6590568      PMCID: PMC425236          DOI: 10.1172/JCI111498

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Cell fusion induced by herpes simplex virus is promoted and suppressed by different viral glycoproteins.

Authors:  R Manservigi; P G Spear; A Buchan
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin.

Authors:  T R Rutherford; J B Clegg; D J Weatherall
Journal:  Nature       Date:  1979-07-12       Impact factor: 49.962

3.  Induction of hemoglobin accumulation in human K562 cells by hemin is reversible.

Authors:  A Dean; F Erard; A P Schneider; A N Schechter
Journal:  Science       Date:  1981-04-24       Impact factor: 47.728

4.  New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase alpha.

Authors:  J A Huberman
Journal:  Cell       Date:  1981-03       Impact factor: 41.582

5.  Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukemia cells.

Authors:  J Lotem; L Sachs
Journal:  Int J Cancer       Date:  1980-05-15       Impact factor: 7.396

6.  The heritable nature of clonal characteristics in acute myeloblastic leukemia.

Authors:  E A McCulloch; R N Buick; J E Curtis; H A Messner; J S Senn
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

7.  Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.

Authors:  P P Major; E M Egan; G P Beardsley; M D Minden; D W Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

8.  Correlation of cytotoxicity with incorporation of ara-C into DNA.

Authors:  D W Kufe; P P Major; E M Egan; G P Beardsley
Journal:  J Biol Chem       Date:  1980-10-10       Impact factor: 5.157

9.  Evidence for double replication of chromosomal DNA segments as a general consequence of DNA replication inhibition.

Authors:  D M Woodcock; I A Cooper
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

10.  Embryonic erythroid differentiation in the human leukemic cell line K562.

Authors:  T Rutherford; J B Clegg; D R Higgs; R W Jones; J Thompson; D J Weatherall
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

View more
  18 in total

1.  Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.

Authors:  Li Yin; Rehan Ahmad; Michio Kosugi; Takeshi Kawano; David Avigan; Richard Stone; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

2.  The DNA methylation system in proliferating and differentiated cells.

Authors:  G P Pfeifer; S D Steigerwald; S Grünwald
Journal:  Cell Biophys       Date:  1989 Aug-Oct

3.  Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes.

Authors:  Ruijuan Xu; Wei Sun; Junfei Jin; Lina M Obeid; Cungui Mao
Journal:  FASEB J       Date:  2010-03-05       Impact factor: 5.191

4.  Cytosine arabinoside reduces the numbers of granulocyte macrophage colony forming cells (GM-CFC) and high proliferative potential colony forming cells (HPP-CFC) in vivo in mice.

Authors:  Stanley Teleka; Alexander Chijuwa; Edward Senga; John E Chisi
Journal:  Malawi Med J       Date:  2011-12       Impact factor: 0.875

5.  Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors.

Authors:  Tanja Musch; Yuva Oz; Frank Lyko; Achim Breiling
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

6.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

8.  Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin.

Authors:  G Feriotto; C Nastruzzi; R Barbieri; R Gambari
Journal:  Blut       Date:  1988-07

9.  The effect of cytosine arabinoside upon mitochondrial staining kinetics in human hematopoietic cells.

Authors:  C Haanen; P Muus; A Pennings
Journal:  Histochemistry       Date:  1986

10.  An erythroid specific nuclear factor binding to the proximal CACCC box of the beta-globin gene promoter.

Authors:  R Mantovani; N Malgaretti; S Nicolis; B Giglioni; P Comi; N Cappellini; M T Bertero; F Caligaris-Cappio; S Ottolenghi
Journal:  Nucleic Acids Res       Date:  1988-05-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.